Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
Would you offer adjuvant therapy for a patient with Stage IIIB melanoma (pT2aN1c) (microsatellite only) following wide excision with negative SLN?
NCCN guidelines suggest observation
Related Questions
How do you approach patients with recurrent BRAF negative melanoma and resected oligo-metastasis after completing one year of adjuvant nivolumab?
When would you offer nivolumab/relatlimab to a metastatic melanoma patient following progression on BRAF/MEK targeted therapy?
In what scenario would you consider dual IO and TKI therapy in advanced stage melanoma?
What second line treatment would you recommend to a patient with metastatic mucosal melanoma that is BRAF and C-KIT wildtype that has progressed after ipilimumab/nivolumab?
How would you approach a patient with clinical T3N1 anorectal malignant melanoma referred by a surgeon for neoadjuvant therapy?
What systemic therapy would you offer a patient with metastatic melanoma who is BRAF WT and developed metastases while on adjuvant nivolumab?
What are your top takeaways in Melanoma from ASCO 2022?
What criteria do you use to determine the resectability of mucosal melanoma of the H&N region?
Any role for adjuvant systemic therapy for resected sebaceous skin carcinoma?
Based on the results of SWOG S1801, neoadjuvant vs adjuvant pembrolizumab for resected stage IIIB-IV melanoma, are you starting to recommend neoadjuvant pembro for your patients?